New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:16 EDTEWEdwards receives CE Mark for advances SAPIEN 3 value
Edwards Lifesciences announced that it has received CE Mark in Europe and is initiating the launch of its most advanced transcatheter aortic valve, the Edwards SAPIEN 3 valve. The SAPIEN 3 valve builds upon Edwards' decades of experience in the development of tissue heart valves, and the proven benefits of the Edwards SAPIEN valves. The new valve has an outer skirt -- a cuff of fabric surrounding the valve frame -- providing a seal to address paravalvular leak. The effectiveness of this solution is supported by the limited clinical experience, as detailed in two first-in-human feasibility studies, which demonstrated that significant paravalvular leak was eliminated during transcatheter aortic valve implantation. The SAPIEN 3 valve is the only commercial transcatheter heart valve that can be delivered through a low-profile 14 French expandable sheath, which has shown through early clinical experience a low rate of complications. The valve can be implanted through multiple approaches: transfemoral, transapical or transaortic. Once implanted, the discreet valve anchors in the aortic annulus. In the United States, the Edwards SAPIEN 3 valve is an investigational device being studied in the PARTNER II Trial and is not yet available for sale in the country.
News For EW From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
07:58 EDTEWEdwards Lifesciences price target raised to $179 from $157 at Stifel
Subscribe for More Information
07:46 EDTEWEdwards Lifesciences price target raised to $178 from $160 at Canaccord
Subscribe for More Information
07:43 EDTEWEdwards Lifesciences price target raised to $185 from $155 at Leerink
Subscribe for More Information
07:23 EDTEWEdwards Lifesciences price target raised to $168 from $155 at JPMorgan
Subscribe for More Information
July 28, 2015
16:30 EDTEWEdwards Lifesciences sees Q3 EPS 92c-$1.00, consensus 98c
Sees Q3 revenue $580M-$620M, consensus $587.06M.
16:28 EDTEWEdwards Lifesciences raises FY15 EPS view to $4.30-44.40, consensus $4.28
Backs FY15 revenue view $2.3B-$2.5B, consensus $2.41B
16:26 EDTEWEdwards Lifesciences reports Q2 EPS $1.13 , consensus $1.05
Subscribe for More Information
15:21 EDTEWNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use